418 related articles for article (PubMed ID: 34531155)
1. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
Scully KJ; Marchetti P; Sawicki GS; Uluer A; Cernadas M; Cagnina RE; Kennedy JC; Putman MS
J Cyst Fibros; 2022 Mar; 21(2):258-263. PubMed ID: 34531155
[TBL] [Abstract][Full Text] [Related]
2. Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF.
Scully KJ; Brenner L; Martin K; Ruazol M; Sawicki GS; Uluer A; Neuringer I; Yonker LM; Sicilian L; Putman MS
Front Endocrinol (Lausanne); 2024; 15():1293709. PubMed ID: 38379863
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
4. Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
Wang A; Lee M; Keller A; Jian S; Lowe K; Finklea JD; Jain R
J Cyst Fibros; 2024 Jan; 23(1):91-98. PubMed ID: 37244841
[TBL] [Abstract][Full Text] [Related]
5. Effect of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients.
Klimeš F; Voskrebenzev A; Gutberlet M; Speth M; Grimm R; Dohna M; Hansen G; Wacker F; Renz DM; Dittrich AM; Vogel-Claussen J
Eur Radiol; 2024 Jan; 34(1):80-89. PubMed ID: 37548691
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
[TBL] [Abstract][Full Text] [Related]
7. Improvements in Glucose Regulation in Children and Young People with Cystic Fibrosis-Related Diabetes following Initiation of Elexacaftor/Tezacaftor/Ivacaftor.
Park J; Walsh A; Kerr S; Woodland C; Southward S; Deakin M; Senniappan S; Thursfield R
Horm Res Paediatr; 2024; 97(1):94-98. PubMed ID: 37040724
[TBL] [Abstract][Full Text] [Related]
8. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
[TBL] [Abstract][Full Text] [Related]
9. Use of cystic fibrosis inhaled medication before and after elexacaftor/tezacaftor/ivacaftor initiation.
Manika K; Diamantea F; Tsakona A; Kakolyris A; Sopiadou A; Kotoulas SC; Sionidou M; Kirvasili SS; Hadji-Mitrova M; Papadaki E; Chrysochoou EA; Hatziagorou E
J Cyst Fibros; 2024 Jan; 23(1):29-31. PubMed ID: 37169616
[TBL] [Abstract][Full Text] [Related]
10. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
Nichols DP; Paynter AC; Heltshe SL; Donaldson SH; Frederick CA; Freedman SD; Gelfond D; Hoffman LR; Kelly A; Narkewicz MR; Pittman JE; Ratjen F; Rosenfeld M; Sagel SD; Schwarzenberg SJ; Singh PK; Solomon GM; Stalvey MS; Clancy JP; Kirby S; Van Dalfsen JM; Kloster MH; Rowe SM;
Am J Respir Crit Care Med; 2022 Mar; 205(5):529-539. PubMed ID: 34784492
[No Abstract] [Full Text] [Related]
11. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
Vonk SEM; Lub R; Weersink EJM; Beuers U; Mathôt RAA; Kemper EM; Altenburg J;
Clin Ther; 2024 Feb; 46(2):154-158. PubMed ID: 38042631
[TBL] [Abstract][Full Text] [Related]
12. Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population.
Smith S; Borchardt M
J Manag Care Spec Pharm; 2022 Jul; 28(7):721-731. PubMed ID: 35737861
[No Abstract] [Full Text] [Related]
13. Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis.
Petersen MC; Begnel L; Wallendorf M; Litvin M
J Cyst Fibros; 2022 Mar; 21(2):265-271. PubMed ID: 34862121
[TBL] [Abstract][Full Text] [Related]
14. Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series.
Gramegna A; De Petro C; Leonardi G; Contarini M; Amati F; Meazza R; Carugo S; Blasi F
J Cyst Fibros; 2022 Sep; 21(5):885-887. PubMed ID: 35450770
[TBL] [Abstract][Full Text] [Related]
15. Impact of chronic medication de-escalation in patients with cystic fibrosis taking elexacaftor, tezacaftor, ivacaftor: A retrospective review.
Guenther EL; McCoy KS; Eisner M; Bai S; Nemastil CJ; Novak KJ; Johnson T; Stephan EM
J Cyst Fibros; 2024 Jan; 23(1):32-37. PubMed ID: 37069044
[TBL] [Abstract][Full Text] [Related]
16. Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients.
Ramos KJ; Guimbellot JS; Valapour M; Bartlett LE; Wai TH; Goss CH; Pilewski JM; Faro A; Diamond JM;
J Cyst Fibros; 2022 Sep; 21(5):745-752. PubMed ID: 35474016
[TBL] [Abstract][Full Text] [Related]
17. Impact of elexacaftor/tezacaftor/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index.
Patel T; McBennett K; Sankararaman S; Schindler T; Sundaram K; Minich NM; Malay S; Kutney K
Pediatr Pulmonol; 2024 Mar; 59(3):734-742. PubMed ID: 38179878
[TBL] [Abstract][Full Text] [Related]
18. Eradication of Mycobacterium abscessus infection in cystic fibrosis with initiation of Elexacaftor/Tezacaftor/Ivacaftor.
McParland C; Nunn M; Marras TK; Chiasson M
J Cyst Fibros; 2024 Jan; 23(1):38-40. PubMed ID: 37076409
[TBL] [Abstract][Full Text] [Related]
19. Fetal drug exposure after maternally administered CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor in a rat model.
Li D; Zhu Y; Donnelley M; Parsons D; Habgood MD; Schneider-Futschik EK
Biomed Pharmacother; 2024 Feb; 171():116155. PubMed ID: 38232663
[TBL] [Abstract][Full Text] [Related]
20. Analysis of iron status after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
James A; Li G; List R; Lonabaugh K; Smith AD; Barros A; Somerville L; Albon D
Pediatr Pulmonol; 2024 Mar; 59(3):669-678. PubMed ID: 38088203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
